transmembrane protein 163Genealiases: DC29 · HLD25 · SLC30A11 · SV31
Q-omics provides the consensus-scored TMEM163 profile across patient tissues and cancer cell-line models. TMEM163 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TMEM163 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, TMEM163 RNA expression shows 15,413 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where TMEM163 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM163 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM163 survival associations across molecular data types. TMEM163 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM163 RNA expression–survival associations across cancer types. High TMEM163 expression shows unfavorable associations in UVM and LIHC, but favorable associations in LUAD, DLBC, BLCA and LGG. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify UVM as the clearest survival context for TMEM163 RNA expression.
This table summarizes TMEM163 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM163. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM163 shows lower tumor expression in LUAD and LUSC and higher tumor expression in KIRC, THCA, HNSC and KIRP. The KIRC box plot shows higher TMEM163 RNA expression in tumor versus normal tissue (log2 FC = +0.855, t-test p < 0.001).
This table shows molecular features associated with TMEM163 in patient tissues and cancer cell lines. In patient samples, TMEM163 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM163 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
